Previous close | 2.0400 |
Open | 2.0566 |
Bid | 1.9000 x 100 |
Ask | 1.9700 x 300 |
Day's range | 1.9500 - 2.0566 |
52-week range | 1.3300 - 4.2980 |
Volume | |
Avg. volume | 351,786 |
Market cap | 75.12M |
Beta (5Y monthly) | 2.78 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.0900 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.42 |
BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May. Sidoti May 2024 Virtual Investor ConferenceFormat: Company PresentationDate and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET Location: Virtual Th
Viewing insider transactions for Athira Pharma, Inc.'s ( NASDAQ:ATHA ) over the last year, we see that insiders were...
Experienced clinical development leader with a strong track record of advancing therapeutics from early development to approval and commercializationBOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 ye